Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PSMB1 | P20618 | 7/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 7/20 | 0.40 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL871366 | 0.87 | LTA4H (0.54) | LTA4HKDM4EPSMB1PSMB5PSMB2 | |
| SCHEMBL585479 | 0.86 | PSMB1 (0.55) | LTA4HKDM4EPSMB1PSMB5PSMB2 | |
| SCHEMBL171775 | 0.85 | ALDH1A1 (0.55) | LTA4HKDM4EPSMB1PSMB5HRH3 | |
| SCHEMBL12512950 | 0.85 | LTA4H (0.37) | LTA4HKDM4EPSMB1PSMB5PSMB2 | |
| SCHEMBL18844624 | 0.81 | HRH3 (0.52) | HRH3ALDH1A1 | |
| SCHEMBL18824777 | 0.81 | HRH3 (0.56) | HRH3 | |
| SCHEMBL1367081 | 0.81 | LTA4H (0.52) | LTA4HKDM4EHRH3NPC1RAB9A | |
| SCHEMBL237631 | 0.80 | HRH3 (0.58) | HRH3 | |
| SCHEMBL29602879 | 0.80 | PSMB1 (0.43) | LTA4HKDM4EPSMB1PSMB5PSMB2 | |
| SCHEMBL25301027 | 0.79 | LTA4H (0.41) | LTA4HKDM4EPSMB1PSMB5PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | AOC3, CBR3, IDH3B | LTA4H 2560/4885KDM4E 1645/4885PSMB1 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.